Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
View Older Stories
-
Horizon Therapeutics (HZNP) PT Raised to $140 at Cowen, Following Earnings
-
Cowen Pounds the Table on Horizon Therapeutics (HZNP), Says Add to Positions Before Earnings
-
Horizon Therapeutics (HZNP) Tepezza is Now Underway, Add Stock - Cowen
-
Horizon Therapeutics plc to Present at the Cowen and Company 41st Annual Health Care Conference
-
Horizon Therapeutics (HZNP) PT Raised to $120 at Cowen
-
Cowen's Tepezza Survey Confirms Investor Expectations Remain Low, Horizon Therapeutics (HZNP) PT Reiterated at $115
-
Horizon Therapeutics (HZNP) PT Raised to $115 at Cowen Following Q3 Results
-
Horizon Therapeutics plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares
-
Horizon Therapeutics (HZNP) Prices 11.8M Share Offering at $71
-
Horizon Therapeutics plc Announces Pricing of Public Offering of Ordinary Shares
-
Horizon Therapeutics (HZNP) Announces Proposed $700M Public Offering of Ordinary Shares
-
Horizon Therapeutics plc Announces Proposed Public Offering of Ordinary Shares
-
Horizon Therapeutics (HZNP) PT Raised to $100 at Cowen
-
Horizon Therapeutics (HZNP) PT Raised to $55 at Cowen
-
Horizon Therapeutics (HZNP) PT Raised to $50 at Cowen
-
Horizon Therapeutics plc to Present at the Cowen and Company 40th Annual Health Care Conference
-
Horizon Pharma (HZNP) PT Raised to $41 at Cowen
-
Horizon Pharma (HZNP) Volatile Following FDA Briefing Docs for Teprotumumab
-
Horizon Pharma (HZNP) PT Raised to $39 at Cowen
-
Horizon Pharma (HZNP) PT Raised to $35 at Cowen
-
Horizon Pharma plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Horizon Pharma (HZNP) Prices 12.245M Share Common Offering at $24.50/Sh
-
Horizon Pharma plc Announces Pricing of Public Offering of Ordinary Shares
-
Pre-Open Stock Movers 03/06: (ANF) (ZAYO) (AMBA) Higher; (VLRX) (CLDX) (PRMW) Lower (more...)
-
Horizon Pharma (HZNP) to Offer $300M in Common Stock
-
Horizon Pharma plc Announces Proposed Public Offering of Ordinary Shares
-
Horizon Pharma (HZNP) PT Raised to $33 at Cowen
-
Horizon Pharma plc to Participate in Cowen and Company 39th Annual Health Care Conference
-
Horizon Pharma (HZNP) PT Raised to $25 at Cowen
-
Horizon Pharma (HZNP) Primary Care Should be Viewed as Strategic/Monetizeable, Not Core - Cowen
-
Horizon Pharma plc to Participate in the Cowen and Company 38th Annual Health Care Conference
-
Drugmakers raise 2018 U.S. prices, stick to self-imposed limits
-
Horizon Pharma (HZNP) PT Lowered to $20 at Cowen; Valuation Suggests Investors Step in Here
-
Horizon Pharma plc to Participate in Cowen and Company 37th Annual Health Care Conference
-
Notable Mergers and Acquisitions 9/12: (AGU)/(POT) (HPQ) (HZNP)/(RPTP) (OTEX)
-
Horizon Pharma plc (HZNP) to Acquire Raptor Pharmaceutical (RPTP) for $800M
-
Horizon Pharma plc to Acquire Raptor Pharmaceutical Corp. as Further Step in Building Leading Rare Disease Business
-
Horizon Pharma plc to Participate in Cowen and Company 36th Annual Health Care Conference
-
Notable Analyst Rating Changes 11/23: (CMG) (JRVR) (PBF) Upgraded; (TXTR) (CTCT) (CAVM) Downgraded
-
Horizon Pharma plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Horizon Pharma (HZNP) Prices Larger 15.35M Common Offering at $28.25/Share
-
Horizon Pharma plc Announces Pricing of Public Offering of Ordinary Shares
-
Horizon Pharma (HZNP) to Offer 12M Common Shares
-
Horizon Pharma plc Announces Proposed Public Offering of Ordinary Shares
-
Notable Mergers and Acquisitions 3/30: (CTRX)/(UNH) (TEVA)/(ASPX) (HZNP)/(HPTX) (ICEL)
-
Horizon Pharma (HZNP) to Acquire Hyperion Therapeutics (HPTX) in $1.1B Deal
-
Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per Share or $1.1 Billion in Cash
-
Horizon Pharma plc Closes Offering of $400 Million of 2.50% Exchangeable Senior Notes, Including Exercise in Full of Option to Purchase Additional Notes
-
Horizon Pharma plc Prices Offering of $350 Million of 2.50% Exchangeable Senior Notes
-
Horizon Pharma (HZNP) Prices 11.66M Common Secondary at $12.05/Share